121.50 +0.08 (0.07%)
After hours: 5:34PM EST
|Bid||121.50 x 100|
|Ask||130.85 x 2000|
|Day's Range||118.89 - 121.47|
|52 Week Range||45.00 - 147.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 3, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.12|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
The Cambridge, Massachusetts-based company said it had a loss of $1.48 per share. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2017 and highlighted recent progress in advancing its pipeline.
NEW YORK, Feb. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Flotek ...
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 8:30 AM ...
According to Sanofi’s (SNY) 2020 road map, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space. The company’s acquisition of Bioverativ (BIVV), which is aimed at expanding Sanofi’s leadership from genetic diseases into hemophilia, emphasizes this underlying goal.
Affimed NV (NASDAQ:AFMD) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were big movers heading into the close of last wee week in biotech. Both have put out fresh news rooted in their respective lead development programs and both have picked up some strength on the back of the development. Here’s a look at what happened and what […] The post Affimed, Alnylam Are End Of The Week Movers In Biotech appeared first on Market Exclusive.
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hereditary ATTR amyloidosis.
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S.
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the European Medicines Agency has accepted the Marketing Authorisation Application and initiated its review for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hereditary ATTR amyloidosis.
We hear from executives from Alnylam, Arena Pharmaceuticals, and Spark Therapeutics at the biggest healthcare conference of the year.
Trump's reported remarks about Haiti and some African countries during an Oval Office meeting with lawmakers on Thursday drew swift condemnation from prominent executives across a range of industries. Among them was Maraganore, who has led Alnylam (ALNY) for more than 15 years, and was appointed last year as chair of the Biotechnology Innovation Organization, or BIO. On Friday morning, Maraganore retweeted a New York Times story about Trump’s remarks, and wrote: “My Mom and Dad came to this country from what was then a ‘s***hole.’ They loved this country.